Bank of America’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-197,794
| Closed | -$1.19M | – | 7562 |
|
|
2019
Q4 | $1.19M | Sell |
197,794
-147,602
| -43% | -$854K | ﹤0.01% | 4378 |
|
|
2019
Q3 | $1.24M | Buy |
345,396
+15,112
| +5% | +$58.3K | ﹤0.01% | 4403 |
|
|
2019
Q2 | $886K | Sell |
330,284
-147,518
| -31% | -$436K | ﹤0.01% | 4648 |
|
|
2019
Q1 | $1.42M | Buy |
477,802
+284,300
| +147% | +$698K | ﹤0.01% | 4263 |
|
|
2018
Q4 | $307K | Sell |
193,502
-319,645
| -62% | -$904K | ﹤0.01% | 5233 |
|
|
2018
Q3 | $1.89M | Buy |
513,147
+96,330
| +23% | +$287K | ﹤0.01% | 4022 |
|
|
2018
Q2 | $1.18M | Buy |
416,817
+52,634
| +14% | +$179K | ﹤0.01% | 4372 |
|
|
2018
Q1 | $1.35M | Sell |
364,183
-78,595
| -18% | -$257K | ﹤0.01% | 4173 |
|
|
2017
Q4 | $1.27M | Buy |
442,778
+37,991
| +9% | +$138K | ﹤0.01% | 4324 |
|
|
2017
Q3 | $1.82M | Sell |
404,787
-78,142
| -16% | -$347K | ﹤0.01% | 4061 |
|
|
2017
Q2 | $2.22M | Sell |
482,929
-47,245
| -9% | -$190K | ﹤0.01% | 3789 |
|
|
2017
Q1 | $2.23M | Sell |
530,174
-6,749
| -1% | -$28K | ﹤0.01% | 3772 |
|
|
2016
Q4 | $2.22M | Buy |
536,923
+22,072
| +4% | +$117K | ﹤0.01% | 3687 |
|
|
2016
Q3 | $4.17M | Buy |
514,851
+14,434
| +3% | +$123K | ﹤0.01% | 2984 |
|
|
2016
Q2 | $3.9M | Buy |
500,417
+4,119
| +0.8% | +$35.3K | ﹤0.01% | 3014 |
|
|
2016
Q1 | $3.83M | Sell |
496,298
-101,238
| -17% | -$741K | ﹤0.01% | 2996 |
|
|
2015
Q4 | $6.45M | Sell |
597,536
-290,949
| -33% | -$2.64M | ﹤0.01% | 2686 |
|
|
2015
Q3 | $6.14M | Sell |
888,485
-67,620
| -7% | -$551K | ﹤0.01% | 2683 |
|
|
2015
Q2 | $8.47M | Buy |
956,105
+374,460
| +64% | +$3.54M | ﹤0.01% | 2088 |
|
|
2015
Q1 | $5.74M | Buy |
581,645
+249,485
| +75% | +$3.12M | ﹤0.01% | 2353 |
|
|
2014
Q4 | $4.07M | Sell |
332,160
-141,261
| -30% | -$1.73M | ﹤0.01% | 2741 |
|
|
2014
Q3 | $4.72M | Buy |
473,421
+420,639
| +797% | +$3.9M | ﹤0.01% | 2622 |
|
|
2014
Q2 | $399K | Buy |
52,782
+41,416
| +364% | +$165K | ﹤0.01% | 4849 |
|
|
2014
Q1 | $37K | Sell |
11,366
-102,152
| -90% | -$358K | ﹤0.01% | 6598 |
|
|
2013
Q4 | $377K | Sell |
113,518
-656,072
| -85% | -$1.9M | ﹤0.01% | 5016 |
|
|
2013
Q3 | $2.32M | Buy |
769,590
+276,266
| +56% | +$1.89M | ﹤0.01% | 3117 |
|
|
2013
Q2 | $4.04M | Buy |
+493,324
| New | +$3.77M | ﹤0.01% | 2490 |
|
Bank of America's ACHN Position: Q1 2020 in Review
Bank of America sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 197,794 shares — an estimated $1.19M sold.
Bank of America first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $8.47M in Q2 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Bank of America reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Bank of America sold 197,794 Achillion Pharmaceuticals shares in Q1 2020, an estimated $1.19M.
- Bank of America first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
- Bank of America's Achillion Pharmaceuticals position peaked at $8.47M in Q2 2015.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Bank of America's 13F filing for Q1 2020, filed 15 May 2020.